208 related articles for article (PubMed ID: 10785369)
1. Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3.
Achen MG; Roufail S; Domagala T; Catimel B; Nice EC; Geleick DM; Murphy R; Scott AM; Caesar C; Makinen T; Alitalo K; Stacker SA
Eur J Biochem; 2000 May; 267(9):2505-15. PubMed ID: 10785369
[TBL] [Abstract][Full Text] [Related]
2. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers.
Stacker SA; Stenvers K; Caesar C; Vitali A; Domagala T; Nice E; Roufail S; Simpson RJ; Moritz R; Karpanen T; Alitalo K; Achen MG
J Biol Chem; 1999 Nov; 274(45):32127-36. PubMed ID: 10542248
[TBL] [Abstract][Full Text] [Related]
3. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
Joukov V; Pajusola K; Kaipainen A; Chilov D; Lahtinen I; Kukk E; Saksela O; Kalkkinen N; Alitalo K
EMBO J; 1996 Jan; 15(2):290-98. PubMed ID: 8617204
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).
Achen MG; Jeltsch M; Kukk E; Mäkinen T; Vitali A; Wilks AF; Alitalo K; Stacker SA
Proc Natl Acad Sci U S A; 1998 Jan; 95(2):548-53. PubMed ID: 9435229
[TBL] [Abstract][Full Text] [Related]
5. The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man.
Baldwin ME; Catimel B; Nice EC; Roufail S; Hall NE; Stenvers KL; Karkkainen MJ; Alitalo K; Stacker SA; Achen MG
J Biol Chem; 2001 Jun; 276(22):19166-71. PubMed ID: 11279005
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
[TBL] [Abstract][Full Text] [Related]
7. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D.
McColl BK; Baldwin ME; Roufail S; Freeman C; Moritz RL; Simpson RJ; Alitalo K; Stacker SA; Achen MG
J Exp Med; 2003 Sep; 198(6):863-8. PubMed ID: 12963694
[TBL] [Abstract][Full Text] [Related]
8. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K
J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269
[TBL] [Abstract][Full Text] [Related]
9. Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2.
Kirkin V; Mazitschek R; Krishnan J; Steffen A; Waltenberger J; Pepper MS; Giannis A; Sleeman JP
Eur J Biochem; 2001 Nov; 268(21):5530-40. PubMed ID: 11683876
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium.
Paavonen K; Mandelin J; Partanen T; Jussila L; Li TF; Ristimaki A; Alitalo K; Konttinen YT
J Rheumatol; 2002 Jan; 29(1):39-45. PubMed ID: 11824969
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1.
Wise LM; Veikkola T; Mercer AA; Savory LJ; Fleming SB; Caesar C; Vitali A; Makinen T; Alitalo K; Stacker SA
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):3071-6. PubMed ID: 10077638
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
13. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development.
Kukk E; Lymboussaki A; Taira S; Kaipainen A; Jeltsch M; Joukov V; Alitalo K
Development; 1996 Dec; 122(12):3829-37. PubMed ID: 9012504
[TBL] [Abstract][Full Text] [Related]
14. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3.
Mäkinen T; Veikkola T; Mustjoki S; Karpanen T; Catimel B; Nice EC; Wise L; Mercer A; Kowalski H; Kerjaschki D; Stacker SA; Achen MG; Alitalo K
EMBO J; 2001 Sep; 20(17):4762-73. PubMed ID: 11532940
[TBL] [Abstract][Full Text] [Related]
15. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro.
Marconcini L; Marchio S; Morbidelli L; Cartocci E; Albini A; Ziche M; Bussolino F; Oliviero S
Proc Natl Acad Sci U S A; 1999 Aug; 96(17):9671-6. PubMed ID: 10449752
[TBL] [Abstract][Full Text] [Related]
16. A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability.
Stacker SA; Vitali A; Caesar C; Domagala T; Groenen LC; Nice E; Achen MG; Wilks AF
J Biol Chem; 1999 Dec; 274(49):34884-92. PubMed ID: 10574962
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias.
Dias S; Hattori K; Heissig B; Zhu Z; Wu Y; Witte L; Hicklin DJ; Tateno M; Bohlen P; Moore MA; Rafii S
Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10857-62. PubMed ID: 11553814
[TBL] [Abstract][Full Text] [Related]
18. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
[TBL] [Abstract][Full Text] [Related]
19. Expression of VEGF-C and activation of its receptors VEGFR-2 and VEGFR-3 in trophoblast.
Dunk C; Ahmed A
Histol Histopathol; 2001 Apr; 16(2):359-75. PubMed ID: 11332691
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo.
Arbiser JL; Larsson H; Claesson-Welsh L; Bai X; LaMontagne K; Weiss SW; Soker S; Flynn E; Brown LF
Am J Pathol; 2000 Apr; 156(4):1469-76. PubMed ID: 10751370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
